Indicators of T-cell activation: Correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV+ individuals and healthy controls

Cytometry

Volumn 33, Issue 2, 1998, Pages 115-122

  Lenkei, Rodica ^a   Bratt, Göran ^b   Holmberg, Vivecka ^b   Muirhead, Katharine ^c   Sandström, Eric ^b  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c SciGro Inc   (United States)

Author keywords

Antibody binding capacity; CD38; HIV infection; Quantitative flow cytometry; sCD8

Indexed keywords

CD23 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADP-RIBOSYL CYCLASE; ADULT; AIDS VACCINES; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; CD4 LYMPHOCYTE COUNT; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NAD+ NUCLEOSIDASE; T-LYMPHOCYTE SUBSETS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032190566     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19981001)33:2<115::AID-CYTO5>3.0.CO;2-I     Document Type: Article

References (64)

1. Agostini C, Semenzato G, Vinante F, Sinicco A, Trentin L, Zambello R, Zuppini B, Zanotti R, Siviero F, Veneri D, Foà R, Pizzolo G: Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. Clin Exp Immun 50:146-153, 1989.
2. Bass HZ, Hardy WD, Mitsuyasu RT, Wang Y-K, Cumberland W, Fahey JL: Eleven lymphoid phenotypic markers in HIV infection: Selective changes induced by zidovudine treatment. J Acquir Immun Defic Syndr 5:890-897, 1992.
3. Bass HZ, Nishanian P, Hardy WD, Mitsuyasu RT, Esmail E, Cumberland W, Fahey JL: Immune changes in HIV-infection: Significant correlation and differences in serum markers and lymphoid phenotypic antigens. Clin Immunol Immunopathol 64:63-70, 1992.
4. Benito JM, Zabay JM, Gil J, Bermejo M, Escudero A, Sánchez E, Fernández-Cruz E: Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: Changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens. J Acquir Immune Defic Syndr Hum Retrovirol 14:128-135, 1997.
5. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick N, Sabin C: Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 10:827-834, 1996.
6. Bouscarat F, Levacher-Clergeot M, Dazza MC, Strauss KW, Girard PM, Ruggeri C, Sinet M: Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 12:17-24, 1996.
7. Cesano A, Visonneau S, Deaglio S, Malavasi F, Santoli D: Role of CD38 and its ligand in the regulation of MHC non-restricted cytotoxic T cells. J Immunol 160:1106-1115, 1998.
8. Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, Dianzani U, Stockinger H, Malavasi F: Human CD38 (ADP-Ribosyl Cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 160:395-402, 1998.
9. Di Rosa G, Feito MJ, Bragardo M, Aversa G, Dianzani U, Malavasi F: CD39 and CD26 are associated with CD38 in human NK cells. J Biol Reg Hom Ag 11:12, 1997.
10. Dianzani U, Funaro A, DiFranco D, Garbarino G, Bragardo M, Redoglia V, Buonfiglio D, De Monte LB, Pileri A, Malavasi F: Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. J Immunol 153:952-959, 1994.
11. Fauci AS: Host factors in the pathogenesis of HIV disease. Antibiot Chemother 48:4-12, 1996.
12. Fuchs D, Jager H, Popescu M, Reibnegger G, Werner ER, Dierich MP, Kaboth W, Tilz GP, Wachter H: Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett 26:75-79, 1990.
13. Funaro A, De Monte LB, Dianzani U, Forni M, Malavasi F: Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages. Eur J Immunol 23:2407-2411, 1993.
14. Funaro A, Reinis M, Trubiani O, Santi S, Di Primio R, Malavasi F: CD38 functions are regulated through an internalization step. J Immunol 160:2238-2297, 1998.
15. Giorgi JV, Detels R: T-cell subsets alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort study. Clin Immunol Immunopathol 52:10-18, 1989.
16. Giorgi JV, Liu Z, Hultin L, Cumberland WG, Hennessey K, Detels R, Multicenter AIDS Cohort Study: Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years of follow-up. J Acquir Immune Defic Syndr 6:904-912, 1993.
17. Gougeon ML, Lecoeur H, Dulioust A, Enouf M-G, Crouvoiser M, Goujard C, Debord T, Montagnier L: Programmed cell death in peripheral lymphocytes from HLV-infected persons. Increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 156:3509-3520, 1996.
18. Griffin DE: Immunologic abnormalities accompanying acute and chronic viral infections. Rev Infect Dis 13 (suppl 1):S129-S133, 1991.
19. Griffin D, Ward BJ, Jauregui E, Johnson RT, Vaisberg A: Immune activation in measles. N Engl J Med 320:1667-1672, 1989.
20. Gruters RA, Terpstra FG, De Goede REY, Mulder JW, De Wolf F, Shellenkens PTA, Van Lier RAW, Tersmette M, Miedema F: Immunological and virological markers in individuals progessing from seroconversion to AIDS. AIDS 5:837-844, 1991.
21. Gruters RA, Terpstra FG, De Jong R, Van Noesel CJM, Van Lier RAW, Miedema F: Selective loss of T cell functions in different stages of HIV infection. Early loss of anti-CD3-induced T cell proliferation followed by decreased anti-CD3-induced cytotoxic T lymphocyte generation in AIDS-related complex and AIDS. Eur J Immunol 20:1039-1044, 1990.
22. Heeney IL: AIDS: A disease of impaired Th-cell renewal. Immunol Today 16:515-520, 1995.
23. Ho H-N, Hultin LE, Mitsuyasu RT, Matud JL, Hausner MA, Bockstoce D, Chou C-C, O'Rourke S, Taylor JMG, Giorgi JV: Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 150:3070-3079, 1993.
24. Hultin L, Matud J, Giorgi JV: Tight regulation of CD4 antigen expression on lymphocytes of healthy donors used directly as a fluorescence quantitation standard. Cytometry 8(suppl):90, 1996.
25. Jiang JD, Schlesinger M, Sacks H, Mildvan D, Roboz JP, Bekesi JG: Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. J Clin Immunol 17:185-192, 1997.
26. Kestens L, Vanham G, Gigase P, Young G, Hannet I, Vanlangendonck F, Hulstaert F, Bach AB: Expression of activation antigens HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS 6:793-797, 1992.
27. Kestens L, Vanham G, Vereecken C, Vandenbruaene M, Vercauteren G, Colenbunders RL, Gigase PL: Selective increase of activation antigens HLA-DR and CD38 on CD4+CD45RO+ T Lymphocytes during HIV infection. Clin Exp Immunol 95:436-441, 1994.
28. Kinnon C, Hinshelwood S, Levinski RJ, Lovering R: X-linked agamma-globulinemia - gene cloning and future prospects. Immunol Today 14:554-558, 1993.
29. Landay A, Ohlsson-Wilhelm B, Giorgi JV: Application of flow cytometry to the study of HIV infection. AIDS 4:479-497, 1990.
30. +2 signaling. Adv Exp Med Biol 419:411-419, 1997.
31. Lenkei R, Andersson B: Determination of the antibody binding capacity of lymphocyte membrane antigens by flow cytometry in 58 blood donors. J Immunol Methods 183:267-277, 1995.
32. Lenkei R, Anderson B: High correlations of Anti-CMV titers with lymphocyte activation status and CD57 antibody-binding capacity as estimated with three-color, quantitative flow cytometry in blood donors. Clin Immunol Immunopathol 77:131-138, 1995.
33. Lenkei R, Gratama JW, Rothe G, Schmitz G, D'Hautcourt JL, Årekrans A, Mandy F, Marti G: Performance of calibration standards for antigen quantitation with flow cytometry. Cytometry 33:188-196, 1998.
34. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA: The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: Staging and prognostic value. Clin Exp Immunol 90:376-382, 1992.
35. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV: Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activation markers, or combination of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16:83-92, 1997.
36. + T cells is a marker of poor prognosis in HIV infection: Results of 6 years of follow-up. Cytometry 26:1-7, 1996.
37. Mahalingam M, Pozniak A, McManus TJ, Senaldi G, Vergani D, Peakman M: Abnormalities of CD45 isoform expression in HIV infection. Clin Immunol Immunopathol 81:210-214, 1996.
38. + lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 14:158-162, 1997.
39. Morra M, Zubiaur M, Terhost C, Sancho J, Malavasi F: CD38 is functionally dependent on the TCR/CD3 complex in human T cells. FASEB J 12:581-592, 1998.
40. Nishanian P, Hofmann B, Wang Y, Jackson AL, Detels R, Fahey JL: Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease. AIDS 5:805-812, 1991.
41. Osmond DH, Shiboski S, Bacchetti P, Winger EE, Moss AR: Immune activation markers and AIDS prognosis. AIDS 5:505-511, 1991.
42. Pantaleo G, Graziosi C, Fauci AS: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328:327-335, 1993.
43. Pantaleo G, Fauci AS: New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 13:487-512, 1995.
44. Perfetto SP, Malone JD, Hawkes C, McCrary G, August B, Zhou S, Garner R, Dolan M, Brown AE: CD38 fluorescent intensity on cryopreserved CD8+ T cells predicts HIV disease progression. Cytometry 33:133-137, 1998.
45. Pizzolo G, Vinante F, Morosato L, De Sabata D, Sinicco A, Raiteri R, Agostini C, Semenzato G: Prognostic significance of soluble CD8 serum levels in HIV-1 infection. AIDS 6:133-134, 1992.
46. Plaeger-Marshall S, Isacescu V, O'Rourke S, Bertolli J, Bryson YJ, Stiehm R: T cell activation in pediatric AIDS pathogenesis: Three colour immunophenotyping. Clin Immunol Immunopathol 71:19-26, 1994.
47. Prince HE, Jensen EK: Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr 4:1227-1232, 1991.
48. Prince HE, Jensen ER: HIV-related alterations in CD8 cell subset defined by in vitro survival characteristics. Cell Immunol 134:276-286, 1991.
49. Prince HE, Kleinman S, Czaplicki C, John J, Williams AE: Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J Acquir Immune Defic Syndr 3:525-530, 1990.
50. Pui C-H, Ip SH, Dodge RK, Carrabis S, Brown M, Crist WM, Berard CW, Kung P, Dahl GV, Murphy SB: Serum levels of CD8 antigen in childhood lymphoid malignancies: A possible indicator of increased suppressor cell activity in poor-risk patients. Blood 72:1015-1021, 1988.
51. Pui C-H, Ip SH, Thompson E, Dodge E, Brown M, Wilimas J, Carrabis S, Kung P, Berard CW, Crist WM: Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood 73:209-213, 1989.
52. Reddy MM, Lange M, Grieco MH: Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected populations. J Clin Microbiol 27:257-260, 1989.
53. Rosenberg YJ, Anderson AO, Pabst R: HIV-induced decline in blood CD4/CD8 ratios: Viral killing or altered lymphocyte trafficking? Immunol Today 19:10-17, 1998.
54. Rosenberg ZF, Fauci AS: Immunopathogenesis of HIV Infection. Sexually Transmitted Diseases 8:165-200, 1992.
55. Saxon A, Keld B, Diaz-Sanchez D, Guo BC, Sidell N: B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis. Clin Exp Immunol 102:17-25, 1995.
56. Schwartz A, Fernández-Repollet E, Vogt R, Gratama JW: Standarding flow cytometry: Construction of a standardized fluorescence calibration plot using matching spectral calibrators. Cytometry 26:22-31, 1996.
57. Shubinsky G, Schlesinger M: The CD38 lymphocyte differentiation marker: New insight into its ectoenzymatic activity and its role as a signal transducer. Immunity 7:315-324, 1997.
58. Taylor J, Afrasiabi R, Fahey JL, Korns E, Weaver M, Mitsuyasu R: Prognostically significant classification of immune changes in AIDS with Kaposi's sarcoma. Blood 67:666-671, 1986.
59. Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL: Soluble CD8 during T cell activation. J Immunol 142:2230-2236, 1989.
60. Vogt RF, Marti GE, Schwartz A: Quantitative calibration of fluorescence intensity for clinical and research applications of immunophenotyping by flow cytometry. Rev Biotechn Bioeng 1:147-175, 1995.
61. Wang LQ, Robb CW, Cloyd MW: HIV induces homing of resting T lymphocytes to lymph nodes. Virology 228:141-152, 1997.
62. Wolthers KC, Schuitemaker H, Miedema F: Rapid CD4+ T-cell turnover in HIV-1 infection: A paradigm revisited. Immunol Today 19:44-48, 1998.
63. + cells in human immunodeficiency virus type-1 infection. Clin Immunol Immunopathol 63:126-134, 1992.
64. + lymphocytes precede detectable levels of HIV-1 antibodies in high-risk homosexuals. J Infect Dis 164:183-188, 1991.